However, while EZH2 inhibitors may benefit patients with gain-of-function mutations, individuals with typical WVS caused by loss-of-function or dominant-negative EZH2 variants may require alternative approaches, such as inhibitors of H3K27me3 demethylases KDM6A and KDM6B. Here, EZH2 is linked to Weaver syndrome.